| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
For drugs metabolized by multiple enzymes, precise estimation of the contribution of each metabolic enzyme is important in evaluating the effects of metabolic inhibition by co-administered drugs. Importance of paying attention to the buffer condition in in vitro metabolic studies was confirmed by our study investigating the contribution of CYP2C8 and CYP3A4 in the metabolism of repaglinide. In addition, a physiologically based pharmacokinetic (PBPK) modeling analysis demonstrated the involvement of both hepatic uptake inhibition and metabolic inhibition in the interaction between clarithromycin and glibenclamide. Similar PBPK analyses as in the present study are expected to facilitate the efficiency in drug development and to provide security in medication involving multiple drugs.
|
